Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
39.61
-0.38 (-0.95%)
Mar 4, 2026, 4:00 PM EST - Market closed
Collegium Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 780.57 | 631.45 | 566.77 | 463.93 | 276.87 | Upgrade
|
| Revenue Growth (YoY) | 23.61% | 11.41% | 22.17% | 67.56% | -10.69% | Upgrade
|
| Cost of Revenue | 89.99 | 83.53 | 94.84 | 118.19 | 59.07 | Upgrade
|
| Gross Profit | 690.58 | 547.92 | 471.93 | 345.74 | 217.8 | Upgrade
|
| Selling, General & Admin | 275.6 | 182.98 | 150.71 | 172.19 | 118.96 | Upgrade
|
| Research & Development | - | - | - | 3.98 | 9.45 | Upgrade
|
| Amortization of Goodwill & Intangibles | 221.89 | 165.3 | 145.76 | 131.47 | 67.18 | Upgrade
|
| Operating Expenses | 497.49 | 348.29 | 296.47 | 307.64 | 195.59 | Upgrade
|
| Operating Income | 193.09 | 199.63 | 175.46 | 38.11 | 22.21 | Upgrade
|
| Interest Expense | -82.31 | -73.97 | -83.34 | -63.21 | -21.01 | Upgrade
|
| Interest & Investment Income | 11.29 | 13.98 | 15.62 | 1.05 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | 122.07 | 139.63 | 107.74 | -24.06 | 1.2 | Upgrade
|
| Merger & Restructuring Charges | -9.61 | -29.6 | - | - | -4.58 | Upgrade
|
| Asset Writedown | -0.58 | - | - | -4.79 | - | Upgrade
|
| Legal Settlements | -3.06 | - | -8.5 | - | - | Upgrade
|
| Other Unusual Items | -16.21 | -11.47 | -23.5 | - | - | Upgrade
|
| Pretax Income | 92.62 | 98.57 | 75.73 | -28.85 | -3.37 | Upgrade
|
| Income Tax Expense | 29.75 | 29.38 | 27.58 | -3.85 | -74.89 | Upgrade
|
| Net Income | 62.87 | 69.19 | 48.16 | -25 | 71.52 | Upgrade
|
| Net Income to Common | 62.87 | 69.19 | 48.16 | -25 | 71.52 | Upgrade
|
| Net Income Growth | -9.13% | 43.68% | - | - | 167.33% | Upgrade
|
| Shares Outstanding (Basic) | 32 | 32 | 34 | 34 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 40 | 40 | 42 | 34 | 41 | Upgrade
|
| Shares Change (YoY) | -1.79% | -3.26% | 23.53% | -17.58% | 16.77% | Upgrade
|
| EPS (Basic) | 1.98 | 2.14 | 1.43 | -0.74 | 2.05 | Upgrade
|
| EPS (Diluted) | 1.73 | 1.86 | 1.29 | -0.74 | 1.86 | Upgrade
|
| EPS Growth | -6.56% | 43.56% | - | - | 144.25% | Upgrade
|
| Free Cash Flow | 327.58 | 203.33 | 274.29 | 122.61 | 101.61 | Upgrade
|
| Free Cash Flow Per Share | 8.25 | 5.03 | 6.56 | 3.62 | 2.48 | Upgrade
|
| Gross Margin | 88.47% | 86.77% | 83.27% | 74.52% | 78.66% | Upgrade
|
| Operating Margin | 24.74% | 31.61% | 30.96% | 8.21% | 8.02% | Upgrade
|
| Profit Margin | 8.05% | 10.96% | 8.50% | -5.39% | 25.83% | Upgrade
|
| Free Cash Flow Margin | 41.97% | 32.20% | 48.39% | 26.43% | 36.70% | Upgrade
|
| EBITDA | 419.16 | 368.79 | 324.72 | 172.26 | 91.12 | Upgrade
|
| EBITDA Margin | 53.70% | 58.40% | 57.29% | 37.13% | 32.91% | Upgrade
|
| D&A For EBITDA | 226.07 | 169.16 | 149.26 | 134.15 | 68.92 | Upgrade
|
| EBIT | 193.09 | 199.63 | 175.46 | 38.11 | 22.21 | Upgrade
|
| EBIT Margin | 24.74% | 31.61% | 30.96% | 8.21% | 8.02% | Upgrade
|
| Effective Tax Rate | 32.12% | 29.80% | 36.41% | - | - | Upgrade
|
| Advertising Expenses | 27.78 | 10.66 | 7.41 | 11.74 | 4.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.